Treatment of congenital hypogonadotropic hypogonadism in male patients

Congenital hypogonadotropic hypogonadism (CHH) is characterized by complete or partial failure of pubertal development because of inadequate secretion of gonadotropic hormones. CHH consists of hypogonadotropic hypogonadism with anosmia or hyposmia, Kallmann syndrome, and the normosmic variation norm...

Full description

Saved in:
Bibliographic Details
Published inAnnals of pediatric endocrinology & metabolism Vol. 27; no. 3; pp. 176 - 182
Main Authors Lee, Hae Sang, Shim, Young Suk, Hwang, Jin Soon
Format Journal Article
LanguageEnglish
Published Korean Society of Pediatric Endocrinology 01.09.2022
대한소아내분비학회
Subjects
congenital hypogonadotropic hypogonadism
fertility
puberty
Review
treatment
소아과학
Online AccessGet full text

Cover

More Information
Summary:Congenital hypogonadotropic hypogonadism (CHH) is characterized by complete or partial failure of pubertal development because of inadequate secretion of gonadotropic hormones. CHH consists of hypogonadotropic hypogonadism with anosmia or hyposmia, Kallmann syndrome, and the normosmic variation normosmic idiopathic hypogonadotropic hypogonadism. CHH is one of the few treatable diseases of male infertility, although men with primary testicular dysfunction have irreversibly diminished spermatogenic capacity. The approach to CHH treatment is determined by goals such as developing virilization or inducing fertility. This review focuses on the current knowledge of therapeutic modalities for inducing puberty and fertility in men with CHH.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2287-1012
2287-1292
DOI:10.6065/apem.2244208.104